Caribou Biosciences Inc (CRBU) - Total Liabilities
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) has total liabilities worth $57.46 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Caribou Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See CRBU working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Caribou Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Caribou Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SAB Finance as
PR:SABFG
|
Czech Republic | Kč2.52 Billion |
|
Ge Shen Corporation Bhd
KLSE:7197
|
Malaysia | RM192.84 Million |
|
eGalax_eMPIA Technology
TWO:3556
|
Taiwan | NT$247.89 Million |
|
First Steamship Co Ltd
TW:2601
|
Taiwan | NT$20.68 Billion |
|
Esenboga Elektrik Uretim AS
IS:ESEN
|
Turkey | TL7.91 Billion |
|
AFC Ajax NV
AS:AJAX
|
Netherlands | €254.97 Million |
|
Putnam Master Intermediate Income Trust
NYSE:PIM
|
USA | $41.54 Million |
|
Duta Intidaya Tbk PT
JK:DAYA
|
Indonesia | Rp939.10 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Caribou Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CRBU market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caribou Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $53.19 Million | -11.88% |
| 2024-12-31 | $60.36 Million | -5.40% |
| 2023-12-31 | $63.81 Million | -12.46% |
| 2022-12-31 | $72.89 Million | +33.67% |
| 2021-12-31 | $54.53 Million | -8.33% |
| 2020-12-31 | $59.48 Million | +9.20% |
| 2019-12-31 | $54.47 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more